Skip to main content
Top
Published in: Calcified Tissue International 3/2013

01-03-2013 | Review

The Relationship Among Hypertension, Antihypertensive Medications, and Osteoporosis: A Narrative Review

Authors: Katarina Ilić, Nevena Obradović, Nada Vujasinović-Stupar

Published in: Calcified Tissue International | Issue 3/2013

Login to get access

Abstract

Osteoporosis and hypertension are two frequent diseases among the aging population that share a similar etiopathology and often coexist. Moreover, treatment of hypertension affects bone mineral density and, therefore, can worsen osteoporosis. This narrative review considers the influence of the main etiologic factors that contribute to the development of hypertension and osteoporosis and examines the effect of the most often used antihypertensives on bones. A computerized literature search of relevant English publications regarding the etiology of hypertension and osteoporosis as well as the impact of antihypertensives on osteoporosis from 1996 to 2011 was completed in October 2011. The latest update in the search was performed from May to June 2012. The most relevant nongenetic factors in the etiology of osteoporosis and hypertension are low calcium intake, vitamin D and vitamin K deficiency, high consumption of sodium salt, and the effects of different forms of nitric oxide. Thiazide diuretics are the only antihypertensives that have a positive influence on bone mineral density. For other antihypertensive drugs, the data are conflicting, indicating that they may have a potentially negative or positive influence on bone mineral density and fracture risk reduction. Some studies did not find a correlation between the use of antihypertensives and bone mineral density. Due to the frequent coexistence of hypertension and osteoporosis, when selecting long-term antihypertensive therapy the potential effects of antihypertensive drugs on development, worsening, or improvement of osteoporosis should also be considered.
Literature
1.
go back to reference Pérez-Castrillόn JL, Justo I, Sanz-Cantalapiedra A, Pueyo C, Hernández G, Dueñas A (2005) Effect of the antihypertensive treatment on the bone mineral density and osteoporotic fracture. Curr Hypertens Rev 1:61–66CrossRef Pérez-Castrillόn JL, Justo I, Sanz-Cantalapiedra A, Pueyo C, Hernández G, Dueñas A (2005) Effect of the antihypertensive treatment on the bone mineral density and osteoporotic fracture. Curr Hypertens Rev 1:61–66CrossRef
2.
3.
go back to reference European Society for Clinical and Economic Aspect of Osteoporosis and Osteoarthritis (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428CrossRef European Society for Clinical and Economic Aspect of Osteoporosis and Osteoarthritis (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428CrossRef
5.
go back to reference Metz JA, Morris CD, Roberts LA, McClung MR, McCarron DA (1999) Blood pressure and calcium intake are related to bone density in adult males. Br J Nutr 81:383–388PubMed Metz JA, Morris CD, Roberts LA, McClung MR, McCarron DA (1999) Blood pressure and calcium intake are related to bone density in adult males. Br J Nutr 81:383–388PubMed
6.
go back to reference Cappucio FP, Meilahn E, Zmuda JM, Cauley JA (1999) High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet 354:971–975CrossRef Cappucio FP, Meilahn E, Zmuda JM, Cauley JA (1999) High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet 354:971–975CrossRef
7.
go back to reference Vestergaard P, Rejnmark L, Mosekilde L (2009) Hypertension is a risk factor for fractures. Calcif Tissue Int 84:103–111PubMedCrossRef Vestergaard P, Rejnmark L, Mosekilde L (2009) Hypertension is a risk factor for fractures. Calcif Tissue Int 84:103–111PubMedCrossRef
8.
go back to reference Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 24:581–589PubMedCrossRef Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 24:581–589PubMedCrossRef
9.
go back to reference Lynn H, Kwok T, Wong SYS, Woo J, Leung PC (2006) Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 38:584–588PubMedCrossRef Lynn H, Kwok T, Wong SYS, Woo J, Leung PC (2006) Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 38:584–588PubMedCrossRef
10.
go back to reference Ott SM, LaCroix AZ, Scholes D, Ichikawa L, Wu K (2008) Effects of three years of low-dose thiazides on mineral metabolism in healthy elderly persons. Osteoporos Int 19:1315–1322PubMedCrossRef Ott SM, LaCroix AZ, Scholes D, Ichikawa L, Wu K (2008) Effects of three years of low-dose thiazides on mineral metabolism in healthy elderly persons. Osteoporos Int 19:1315–1322PubMedCrossRef
11.
go back to reference Rang HP et al. (2012) Bone metabolism. In: Rang and Dale`s pharmacology. 7th ed, Churchill Livingstone, Elsevier, Philadelphia, pp 432–441 Rang HP et al. (2012) Bone metabolism. In: Rang and Dale`s pharmacology. 7th ed, Churchill Livingstone, Elsevier, Philadelphia, pp 432–441
12.
go back to reference Power ML, Heaney RP, Kalkwarf HJ et al (1999) The role of calcium in health and disease. Am J Obstet Gynecol 181:1560–1569PubMedCrossRef Power ML, Heaney RP, Kalkwarf HJ et al (1999) The role of calcium in health and disease. Am J Obstet Gynecol 181:1560–1569PubMedCrossRef
13.
go back to reference Zemel MB (2001) Calcium modulation of hypertension and obesity: mechanisms and implications. J Am Coll Nutr 20:428S–435SPubMed Zemel MB (2001) Calcium modulation of hypertension and obesity: mechanisms and implications. J Am Coll Nutr 20:428S–435SPubMed
14.
go back to reference McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR (2004) Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine 23(1):1–10PubMedCrossRef McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR (2004) Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine 23(1):1–10PubMedCrossRef
15.
go back to reference Zitterman A, Schleithoff SS, Koerfer R (2005) Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 94:483–492CrossRef Zitterman A, Schleithoff SS, Koerfer R (2005) Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 94:483–492CrossRef
17.
go back to reference Boonen S, Vanderschueren D, Haentjens P, Lips P (2006) Calcium and vitamin D in the prevention and treatment of osteoporosis—a clinical update. J Intern Med 259:539–552PubMedCrossRef Boonen S, Vanderschueren D, Haentjens P, Lips P (2006) Calcium and vitamin D in the prevention and treatment of osteoporosis—a clinical update. J Intern Med 259:539–552PubMedCrossRef
18.
go back to reference Glerup H, Mikkelsen K, Poulsen L, Hass E, Overbeck S, Andersen H et al (2000) Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int 66(6):419–424PubMedCrossRef Glerup H, Mikkelsen K, Poulsen L, Hass E, Overbeck S, Andersen H et al (2000) Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int 66(6):419–424PubMedCrossRef
19.
go back to reference Mosekilde L (2005) Vitamin D and the elderly. Clin Endocrinol (Oxf) 62:265–281CrossRef Mosekilde L (2005) Vitamin D and the elderly. Clin Endocrinol (Oxf) 62:265–281CrossRef
20.
go back to reference London GM, Guérin AP, Verbeke FH et al (2007) Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18:613–620PubMedCrossRef London GM, Guérin AP, Verbeke FH et al (2007) Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18:613–620PubMedCrossRef
21.
go back to reference Braam LA, Knapen MH, Geusens P et al (2003) Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif Tissue Int 73:21–26PubMedCrossRef Braam LA, Knapen MH, Geusens P et al (2003) Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif Tissue Int 73:21–26PubMedCrossRef
22.
go back to reference Vermeer C, Shearer M, Zittermann A et al (2004) Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. Eur J Nutr 43:325–335PubMedCrossRef Vermeer C, Shearer M, Zittermann A et al (2004) Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. Eur J Nutr 43:325–335PubMedCrossRef
23.
go back to reference Knapen MH J, Schurgers L, Vermeer C (2007) Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int 18:963–972PubMedCrossRef Knapen MH J, Schurgers L, Vermeer C (2007) Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int 18:963–972PubMedCrossRef
24.
go back to reference Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP (2009) Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int 20:197–207PubMedCrossRef Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP (2009) Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int 20:197–207PubMedCrossRef
25.
go back to reference Cranenburg CME, Schurgers JL, Vermeer C (2007) Vitamin K: The coagulation vitamin that became omnipotent. Thromb Haemost 98:120–125PubMed Cranenburg CME, Schurgers JL, Vermeer C (2007) Vitamin K: The coagulation vitamin that became omnipotent. Thromb Haemost 98:120–125PubMed
26.
go back to reference Adams J, Pepping J (2005) Vitamin K in the treatment and prevention of osteoporosis and arterial calcification. Am J Health Syst Pharm 62 Adams J, Pepping J (2005) Vitamin K in the treatment and prevention of osteoporosis and arterial calcification. Am J Health Syst Pharm 62
27.
go back to reference Cockayne S, Adamson J, Lanham-New S, Shearer M, Gilbody S, Torgerson D (2006) Vitamin K and the prevention of fractures—systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166:1256–1261PubMedCrossRef Cockayne S, Adamson J, Lanham-New S, Shearer M, Gilbody S, Torgerson D (2006) Vitamin K and the prevention of fractures—systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166:1256–1261PubMedCrossRef
28.
go back to reference Heaney PR (2006) Role of dietary sodium in osteoporosis. J Am Coll Nutr 25(3):271S–276SPubMed Heaney PR (2006) Role of dietary sodium in osteoporosis. J Am Coll Nutr 25(3):271S–276SPubMed
29.
go back to reference Woo J, Kwok T, Leung J, Tang N (2009) Dietary intake, blood pressure and osteoporosis. J Hum Hypertens 23:451–455PubMedCrossRef Woo J, Kwok T, Leung J, Tang N (2009) Dietary intake, blood pressure and osteoporosis. J Hum Hypertens 23:451–455PubMedCrossRef
30.
go back to reference Karppanen H, Karppanen P, Mervaala E (2005) Why and how to implement sodium, potassium, calcium, and magnesium changes in food items and diets? J Hum Hypertens 19:S10–S19PubMedCrossRef Karppanen H, Karppanen P, Mervaala E (2005) Why and how to implement sodium, potassium, calcium, and magnesium changes in food items and diets? J Hum Hypertens 19:S10–S19PubMedCrossRef
31.
go back to reference Rang HP et al. (2012) The vascular system. In: Rang and Dale`s Pharmacology. 7th ed, Churchill Livingstone, Elsevier, Philadelphia, pp 265–282 Rang HP et al. (2012) The vascular system. In: Rang and Dale`s Pharmacology. 7th ed, Churchill Livingstone, Elsevier, Philadelphia, pp 265–282
32.
go back to reference Khosla S (2011) Is nitroglycerin a novel and inexpensive treatment for osteoporosis? JAMA 305(8):826–827PubMedCrossRef Khosla S (2011) Is nitroglycerin a novel and inexpensive treatment for osteoporosis? JAMA 305(8):826–827PubMedCrossRef
33.
go back to reference Jamal SA, Hamilton CJ, Eastell R, Cummings SR (2011) Effect of nitroglycerin ointment on bone density and strength in postmenopausal women. JAMA 05(8):800–807CrossRef Jamal SA, Hamilton CJ, Eastell R, Cummings SR (2011) Effect of nitroglycerin ointment on bone density and strength in postmenopausal women. JAMA 05(8):800–807CrossRef
34.
go back to reference Rejnmark L, Vestergaard P, Mosekilde L (2006) Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res 21(11):1811–1817PubMedCrossRef Rejnmark L, Vestergaard P, Mosekilde L (2006) Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res 21(11):1811–1817PubMedCrossRef
35.
go back to reference Wimalawansa SJ (2000) Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res 15(11):2240–2244PubMedCrossRef Wimalawansa SJ (2000) Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res 15(11):2240–2244PubMedCrossRef
36.
go back to reference Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR (2009) Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab 94(9):3356–3364PubMedCrossRef Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR (2009) Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab 94(9):3356–3364PubMedCrossRef
37.
go back to reference Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC (2004) Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study. J Bone Miner Res 19:19–24PubMedCrossRef Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC (2004) Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study. J Bone Miner Res 19:19–24PubMedCrossRef
38.
go back to reference Shih TTF, Chang CJ, Tseng WYI et al (2004) Effect of calcium channel blockers on vertebral bone marrow perfusion of the lumbar spine. Radiology 231:24–30PubMedCrossRef Shih TTF, Chang CJ, Tseng WYI et al (2004) Effect of calcium channel blockers on vertebral bone marrow perfusion of the lumbar spine. Radiology 231:24–30PubMedCrossRef
39.
go back to reference Žofkova I, Kancheva RL (1995) The effect of nifedipine on serum parathyroid hormone and calcitonin in postmenopausal women. Life Sci 57(11):1087–1096PubMedCrossRef Žofkova I, Kancheva RL (1995) The effect of nifedipine on serum parathyroid hormone and calcitonin in postmenopausal women. Life Sci 57(11):1087–1096PubMedCrossRef
40.
go back to reference Rejnmark L, Vestergaard P, Mosekilde L (2006) Fracture risk in patients treated with loop diuretics. J Intern Med 259:117–124PubMedCrossRef Rejnmark L, Vestergaard P, Mosekilde L (2006) Fracture risk in patients treated with loop diuretics. J Intern Med 259:117–124PubMedCrossRef
41.
go back to reference Rejnmark L, Vestergaard P, Kassem M et al (2004) Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 75:365–372PubMedCrossRef Rejnmark L, Vestergaard P, Kassem M et al (2004) Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 75:365–372PubMedCrossRef
42.
go back to reference Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L (2006) Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 21:163–170PubMedCrossRef Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L (2006) Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 21:163–170PubMedCrossRef
43.
go back to reference Reid IR, Gamble GD, Grey AB et al (2005) β-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 20:613–618PubMedCrossRef Reid IR, Gamble GD, Grey AB et al (2005) β-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 20:613–618PubMedCrossRef
44.
go back to reference Zacharieva S, Shigarminova R, Nachev E et al (2003) Effect of amlodipine and hormone replacement therapy on blood pressure and bone markers in menopause. Methods Find Exp Clin Pharmacol 25(3):209PubMedCrossRef Zacharieva S, Shigarminova R, Nachev E et al (2003) Effect of amlodipine and hormone replacement therapy on blood pressure and bone markers in menopause. Methods Find Exp Clin Pharmacol 25(3):209PubMedCrossRef
45.
go back to reference Hajjar I (2005) Postural blood pressure changes and orthostatic hypotension in the elderly patient: impact of antihypertensive medications. Drugs Aging 22(1):55–68PubMedCrossRef Hajjar I (2005) Postural blood pressure changes and orthostatic hypotension in the elderly patient: impact of antihypertensive medications. Drugs Aging 22(1):55–68PubMedCrossRef
46.
go back to reference Sowers MR, Clark MK, Jannausch ML, Wallace RB (1993) Body size, estrogen use and thiazide diuretic use affect 5-year radial bone loss in postmenopausal women. Osteoporos Int 3:314–321PubMedCrossRef Sowers MR, Clark MK, Jannausch ML, Wallace RB (1993) Body size, estrogen use and thiazide diuretic use affect 5-year radial bone loss in postmenopausal women. Osteoporos Int 3:314–321PubMedCrossRef
47.
go back to reference Cauley JA, Cummings SR, Seeley DG et al (1993) Effects of thiazide diuretic therapy on bone mass, fractures, and falls. Ann Intern Med 118:666–673PubMed Cauley JA, Cummings SR, Seeley DG et al (1993) Effects of thiazide diuretic therapy on bone mass, fractures, and falls. Ann Intern Med 118:666–673PubMed
48.
go back to reference Jones G, Nguyen Tuan, Sambrook PN, Eisman JA (1995) Thiazide diuretics and fractures: can meta-analysis help? J Bone Miner Res 10:106–111PubMed Jones G, Nguyen Tuan, Sambrook PN, Eisman JA (1995) Thiazide diuretics and fractures: can meta-analysis help? J Bone Miner Res 10:106–111PubMed
49.
go back to reference LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE (2000) Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 133:516–526PubMed LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE (2000) Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 133:516–526PubMed
50.
go back to reference Schoofs MWCJ, van der Klift M, Hofman A et al (2003) Thiazide diuretics and the risk for hip fracture. Ann Intern Med 139:476–482PubMed Schoofs MWCJ, van der Klift M, Hofman A et al (2003) Thiazide diuretics and the risk for hip fracture. Ann Intern Med 139:476–482PubMed
51.
go back to reference Bolland MJ, Ames RW, Horne AM, Orr-Walker BJ, Gamble GD, Reid IR (2007) The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos Int 18:479–486PubMedCrossRef Bolland MJ, Ames RW, Horne AM, Orr-Walker BJ, Gamble GD, Reid IR (2007) The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos Int 18:479–486PubMedCrossRef
52.
go back to reference Cruz DN (2001) The renal tubular Na–Cl co-transporter (NCCT): a potential genetic link between blood pressure and bone density? Nephrol Dial Transpl 16:691–694CrossRef Cruz DN (2001) The renal tubular Na–Cl co-transporter (NCCT): a potential genetic link between blood pressure and bone density? Nephrol Dial Transpl 16:691–694CrossRef
54.
go back to reference Haque SF, Ahmad M, Khan AU, Gupta V, Khan AS (2011) Angiotensin converting enzyme insertion/deletion gene polymorphism and genomic sequence in diabetic nephropathy. Biomed Res 22(2):173–177 Haque SF, Ahmad M, Khan AU, Gupta V, Khan AS (2011) Angiotensin converting enzyme insertion/deletion gene polymorphism and genomic sequence in diabetic nephropathy. Biomed Res 22(2):173–177
55.
go back to reference Schlienger RG, Kraenzlin ME, Jick SS, Meier CR (2004) Use of β-blockers and risk of fractures. JAMA 292:1326–1332PubMedCrossRef Schlienger RG, Kraenzlin ME, Jick SS, Meier CR (2004) Use of β-blockers and risk of fractures. JAMA 292:1326–1332PubMedCrossRef
56.
57.
go back to reference Wiens M, Etminan M, Gill SS, Takkouche B (2006) Effects of antihypertensive drug treatment on fracture outcomes: a meta-analysis of observational studies. J Intern Med 260:350–362PubMedCrossRef Wiens M, Etminan M, Gill SS, Takkouche B (2006) Effects of antihypertensive drug treatment on fracture outcomes: a meta-analysis of observational studies. J Intern Med 260:350–362PubMedCrossRef
58.
go back to reference Souverein PC, Van Staa TP, Egberts ACG, de la Rosette MCH, Cooper C, Leufkens HGM (2003) Use of α-blockers and the risk of hip/femur fractures. J Intern Med 254:548–554PubMedCrossRef Souverein PC, Van Staa TP, Egberts ACG, de la Rosette MCH, Cooper C, Leufkens HGM (2003) Use of α-blockers and the risk of hip/femur fractures. J Intern Med 254:548–554PubMedCrossRef
Metadata
Title
The Relationship Among Hypertension, Antihypertensive Medications, and Osteoporosis: A Narrative Review
Authors
Katarina Ilić
Nevena Obradović
Nada Vujasinović-Stupar
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 3/2013
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-012-9671-9

Other articles of this Issue 3/2013

Calcified Tissue International 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.